Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00603668
Recruitment Status : Completed
First Posted : January 29, 2008
Last Update Posted : March 27, 2013
Information provided by (Responsible Party):
Immunomedics, Inc.